Acadia Pharmaceuticals Adds Complementary Intellectual Property for Serotonin Platform

Acadia Pharmaceuticals Inc. had announced that it has expanded and further strengthened the intellectual property portfolio for its serotonin platform by entering into an agreement to license certain intellectual property rights from Ipsen, an innovation driven international specialty pharmaceutical group.

Acadia has developed a broad serotonin platform comprising a range of chemistries and biological assets. These assets include ACP-103 and follow-on and back-up compounds, which have potential therapeutic applications in a number of CNS indications, including schizophrenia, Parkinson's disease psychosis, and sleep maintenance insomnia. Acadia's intellectual property estate in the serotonin area currently includes 11 issued patents and 81 pending patent applications. The Ipsen agreement provides ACADIA with a non-exclusive license to additional intellectual property rights that complement this serotonin patent portfolio. Under the terms of the agreement, Acadia will make an initial payment of $250,000 to Ipsen, and, if certain conditions are met, Acadia would make additional payments, including milestones, royalties and sublicensing fees for compounds covered by the agreement.

For further information please contact:

Thomas H. Aasen,

Vice President and Chief Financial Officer

Tel: +46 40 601 3400

Email: info@acadia-pharm.com

Or visit: www.acadia-pharm.com